DalCor www.dalcorpharma.com
Founded 2015 · 19 employees on LinkedIn · 1 known investors
Find your way into DalCor www.dalcorpharma.com
471 people in our graph share verified history with the DalCor www.dalcorpharma.com team — schools, employers, funds. One of them is your warm intro.
Lyle McCullochunlockedknows Michael Dixon · together at Price Waterhouse (now PwC) (overlapped)
×10knows the team · via Price Waterhouse (now PwC)
knows the team · via Sanderling Ventures
DalCor Pharmaceuticals is a biopharmaceutical company developing dalcetrapib, a pharmacogenetic precision medicine for cardiovascular disease that targets patients with the ADCY9 AA genotype. The drug is being evaluated in Phase 3 clinical trials to reduce fatal and non-fatal myocardial infarction in post-acute coronary syndrome patients.
Founders & leadership
FL
Fouzia Laghrissi-ThodeinChief Executive Officer
MD
Michael DixoninChief Financial OfficerMichael Dixon serves as Chief Financial Officer of DalCor Pharmaceuticals, a biopharmaceutical company developing precision medicines for cardiovascular disease.
TH
Therese HeinoneninChief Development Officer
DS
Diane SullivanChief Commercial Officer
Investors · 1
Competitors · 5
by search overlapCapricor9 shared keywordsCapricor Therapeutics is a biotechnology company developing allogeneic cardiosphere-derived cell (CDC) and exosome-based therapeutics to treat serious diseases including Duchenne muscular dystrophy. The company uses cell and exosome biology platforms to create novel therapeutic medicines for patient treatment.
Arecor8 shared keywordsAreCor develops proprietary pharmaceutical products for diabetes, obesity, and cardiometabolic diseases using its Arestat technology platform. The company targets areas of high unmet patient need in high-value therapeutic markets.
Bioworld8 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
CeleCor Therapeutics7 shared keywordsCelecor develops zalunfiban (Disaggpro), an investigational platelet inhibitor drug designed for rapid subcutaneous administration by first responders in pre-hospital treatment of STEMI heart attacks. The company focuses on acute cardiovascular care for patients experiencing the most severe form of heart attack.
Xylocor7 shared keywordsXyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage. The company's lead program, XC001, targets refractory angina in patients with limited treatment options.
Companies competing with DalCor www.dalcorpharma.com for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does DalCor www.dalcorpharma.com do?
- DalCor Pharmaceuticals is a biopharmaceutical company developing dalcetrapib, a pharmacogenetic precision medicine for cardiovascular disease that targets patients with the ADCY9 AA genotype. The drug is being evaluated in Phase 3 clinical trials to reduce fatal and non-fatal myocardial infarction in post-acute coronary syndrome patients.
- Who are DalCor www.dalcorpharma.com's investors?
- DalCor www.dalcorpharma.com's investors include Sanderling Ventures.